Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > AEZS's diagnostic test:

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 05, 2024 9:57pm

53 Views

Post# 35864469

RE:AEZS's diagnostic test:

Bing:

Aeterna Zentaris has developed a growth hormone deficiency (GHD) test using macimorelin, which offers several advantages compared to traditional GH-stimulation tests:

Simplicity: The macimorelin test is straightforward and easy to administer. It involves oral administration of macimorelin to the child, followed by blood sample collection within 60 minutes. In contrast, other GH-stimulation tests often require more complex procedures.
Minimal Side Effects: Macimorelin is well-tolerated with minimal side effects. This makes it a more comfortable experience for patients, especially children.
Fewer Blood Draws: Unlike other tests that may involve multiple blood draws, the macimorelin test typically requires only 3 to 4 blood samples. This reduction in blood draws is beneficial for both patients and healthcare providers.
Shorter Duration: The entire process, from administration to blood sampling, is completed in a shorter time frame. This efficiency is advantageous for diagnosing GHD promptly.
Accurate Diagnosis: By measuring growth hormone levels in blood samples, the macimorelin test allows for the determination of GHD based on a predetermined threshold value. If the peak growth hormone level falls below this threshold, it indicates pituitary-related GHD.
Treatment Option: The patent also covers treating the deficiency with synthetic human growth hormone, providing a comprehensive approach to managing GHD.

In summary, Aeterna Zentaris’ macimorelin test offers simplicity, minimal invasiveness, and accurate diagnosis, making it a valuable alternative to traditional GH-stimulation tests 1 2 3

prophetoffactz wrote: Macimorelin is the first and only US Food and Drug Administration (FDA)-approved oral drug indicated for the diagnosis of adult GH deficiency (AGHD), a rare endocrine disorder. In clinical trials, macimorelin demonstrated comparable diagnostic accuracy to the gold standard GH stimulation test, the insulin tolerance test (ITT) [4]. Potential advantages of macimorelin over the ITT include better tolerability and greater convenience. Macimorelin has no absolute contraindications [1], unlike the ITT, which is contraindicated in elderly populations and in patients with cardiovascular disease or seizure disorders [2,[5], [6], [7]].Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study - ScienceDirect